BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rangnekar AS, Fontana RJ. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat. 2013;20:377-384. [PMID: 23647954 DOI: 10.1111/jvh.12039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res. 2015;45:745-754. [PMID: 25196718 DOI: 10.1111/hepr.12416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
2 Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, Karimi Elizee P, Ghazimoghaddam M, Alavian SM. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon. 2016;16:e32703. [PMID: 27110259 DOI: 10.5812/hepatmon.32703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
3 Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 [PMID: 29632428 DOI: 10.3748/wjg.v24.i13.1478] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015;Epub ahead of print. [PMID: 25918016 DOI: 10.1038/tpj.2015.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
5 Wu R, Chi X, Wang X, Sun H, Lv J, Gao X, Yu G, Kong F, Xu H, Hua R, Jiang J, Sun B, Zhong J, Pan Y, Niu J. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. Infect Genet Evol 2016;39:132-40. [PMID: 26820907 DOI: 10.1016/j.meegid.2016.01.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 2013; 19(47): 8924-8928 [PMID: 24379617 DOI: 10.3748/wjg.v19.i47.8924] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
7 Xu J, Zhan Q, Fan Y, Yu Y, Zeng Z. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol 2021;87:104663. [PMID: 33278635 DOI: 10.1016/j.meegid.2020.104663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gauthiez E, Habfast-robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, Moradpour D, Müllhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P; the Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. Liver Int 2017;37:1431-45. [DOI: 10.1111/liv.13401] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
9 Akkarathamrongsin S, Thong VD, Payungporn S, Poovorawan K, Prapunwattana P, Poovorawan Y, Tangkijvanich P. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol. 2014;86:1482-1490. [PMID: 24782280 DOI: 10.1002/jmv.23957] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
10 Win LL, James P, Wong DK. Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection. Dig Dis Sci 2014;59:1946-9. [PMID: 24846795 DOI: 10.1007/s10620-014-3211-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH. Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Gut Liver 2017;11:543-50. [PMID: 28506027 DOI: 10.5009/gnl16530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
12 Liu T, Sha K, Yang L, Wang Y, Zhang L, Liu X, Yang F. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One 2014;9:e91316. [PMID: 24642705 DOI: 10.1371/journal.pone.0091316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS One 2015;10:e0145622. [PMID: 26699619 DOI: 10.1371/journal.pone.0145622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Paterson JC, Miller MH, Dillon JF. Update on the treatment of hepatitis C genotypes 2-6. Curr Opin Infect Dis 2014;27:540-4. [PMID: 25313502 DOI: 10.1097/QCO.0000000000000114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Wong YJ, Cheen MH, Hsiang JC, Kumar R, Tan J, Teo EK, Thurairajah PH. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open 2019;3:210-6. [PMID: 31276038 DOI: 10.1002/jgh3.12139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Ikezaki H, Furusyo N, Hiramine S, Ura K, Mitsumoto-Kaseida F, Takayama K, Shimizu M, Toyoda K, Ogawa E, Kainuma M, Murata M, Hayashi J. Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study. Arch Virol 2016;161:641-8. [PMID: 26660164 DOI: 10.1007/s00705-015-2703-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]